Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to ...

Early data in mice and human tissue indicate that using drugs or gene therapy could allow for cardiac healing in ischemic HF.

CV risk factors don’t just impact heart health, but also affect other organs, including the brain, say experts.

Poor performance on quality metrics carried greater risk of in-hospital mortality no matter where patients initially ...

For many of these conditions, women present later and sicker, and are less likely to be treated appropriately.

The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...

For the investigator-initiated ATTENUATE trial, researchers used the 11 x 34” RADPAD Orange, which Medranda calls a ...

More research is needed to see how this factor could inform risk tools and whether addressing it reduces future disease.

Even modern cancer treatments appear risky for the heart, especially if the radiation dose to the LAD is high.

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.